Algernon NeuroScience Announces 40 Patient Phase 2 Psychedelic Drug DMT Stroke Study

VANCOUVER, British Columbia, Aug. 08, 2023 (GLOBE NEWSWIRE) -- Algernon Pharmaceuticals Inc. (the “Company” or “AGN Pharma”) (CSE: AGN) (FRANKFURT: AGW0) (OTCQB: AGNPF), a Canadian clinical stage pharmaceutical development company, is pleased to announce that its subsidiary Algernon NeuroScience (AGN Neuro), has completed a feasibility study and has finalized its clinical trial design for a 40 patient Phase 2 DMT Stroke study. AGN Neuro is the world’s first company to investigate DMT for the tre

Related Keywords

Canada , Vancouver , British Columbia , United Kingdom , Netherlands , London , City Of , Canadian , British , Christopherj Moreau , Edmundj Safra , David Nutt , Rick Strassman , Algernon Pharmaceuticals , Algernon Pharmaceuticals Inc , Constraint Induced Movement Therapy , Centre For Human Drug Research , Imperial College London , Company Phase , Algernon Neuroscience , Spirit Molecule , Psychedelic Handbook , Human Drug Research , Brain Derived Neurotrophic Factor , Constraint Induced Movement , Stroke , Clinical Trial Design , Psychedelic Effects , Gn Neuro , Mt , Pre Clinical Studies , Neuroplasticity , Phase 2 Study ,